Rein Therapeutics, Inc. (RNTX) — SEC Filings
Rein Therapeutics, Inc. (RNTX) — 50 SEC filings. Latest: 8-K (May 4, 2026). Includes 30 8-K, 6 10-Q, 3 10-K/A.
View Rein Therapeutics, Inc. on SEC EDGAR
Overview
Rein Therapeutics, Inc. (RNTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 11, 2025: Rein Therapeutics, Inc. filed an 8-K on December 11, 2025, to report the termination of a material definitive agreement. The filing does not specify the other party to the agreement or the nature of the agreement, only that it is no longer in effect.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 3 bearish, 47 neutral. The dominant filing sentiment for Rein Therapeutics, Inc. is neutral.
Filing Type Overview
Rein Therapeutics, Inc. (RNTX) has filed 30 8-K, 1 424B5, 2 S-1, 3 10-K/A, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13D/A, 1 SC 13G, 1 SC 13G/A with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of RNTX's 43 recent filings, 3 were flagged as high-risk, 22 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$5.581M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $4.048M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Brian Windsor, Ph.D.
- Daniel K. Donahue
- Dr. Christopher P. Miller
- Dr. Andrew R. Allen
- Muneer A. Satter
- Christopher P. Miller
Industry Context
Rein Therapeutics operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success is often dependent on securing substantial funding and navigating complex clinical trials.
Top Tags
filing (6) · material-agreement (5) · 8-K (5) · corporate-action (5) · financials (5) · name-change (4) · 10-Q (4) · financial-reporting (4) · Biotechnology (3) · Clinical Hold (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $4.048M | Decreased from $12.865 million at December 31, 2024, indicating significant cash burn. |
| Net loss for nine months ended Sep 30, 2025 | $17.904M | Compared to $21.902 million for the same period in 2024, showing a slight reduction in loss. |
| Net loss for three months ended Sep 30, 2025 | $5.581M | Compared to $5.847 million for the same period in 2024. |
| Research and development expenses (Q3 2025) | $1.681M | Decreased from $3.722 million in Q3 2024, reflecting reduced clinical activity. |
| General and administrative expenses (Q3 2025) | $3.811M | Increased from $2.349 million in Q3 2024. |
| Common shares outstanding | 26,286,382 | As of November 10, 2025, indicating potential dilution from prior periods. |
| Net cash used in operating activities (nine months 2025) | $16.141M | Reflects ongoing operational cash burn. |
| Net cash provided by financing activities (nine months 2025) | $7.350M | Primarily from stock and warrant issuances, crucial for sustaining operations. |
| Commission File Number | 001-38130 | Identifies the company's filing with the SEC. |
| I.R.S. Employer Identification Number | 13-4196017 | Company's tax identification number. |
| SEC File Number | 001-38130 | Identifies the company's filing with the SEC. |
| EIN | 13-4196017 | Employer Identification Number for tax purposes. |
| Aggregate gross proceeds | $15,000,000 | Maximum amount Rein Therapeutics may receive from sales of common stock to Yorkville under the SEPA over 36 months |
| Shares of common stock | 10,000,000 | Maximum number of shares offered by the Selling Stockholder in this prospectus |
| Commitment Shares | 213,099 | Shares issued to Selling Stockholder upon SEPA execution as consideration |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Rein Therapeutics, Inc. (RNTX)?
Rein Therapeutics, Inc. has 50 recent SEC filings from Feb 2024 to May 2026, including 30 8-K, 6 10-Q, 3 10-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RNTX filings?
Across 50 filings, the sentiment breakdown is: 3 bearish, 47 neutral. The dominant sentiment is neutral.
Where can I find Rein Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Rein Therapeutics, Inc. (RNTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Rein Therapeutics, Inc.?
Key financial highlights from Rein Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RNTX?
The investment thesis for RNTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Rein Therapeutics, Inc.?
Key executives identified across Rein Therapeutics, Inc.'s filings include Brian Windsor, Ph.D., Daniel K. Donahue, Dr. Christopher P. Miller, Dr. Andrew R. Allen, Muneer A. Satter and 1 others.
What are the main risk factors for Rein Therapeutics, Inc. stock?
Of RNTX's 43 assessed filings, 3 were flagged high-risk, 22 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Rein Therapeutics, Inc.?
Forward guidance and predictions for Rein Therapeutics, Inc. are extracted from SEC filings as they are enriched.